Significantly improved analytical productivity with automated pretreatment operations
New i-Series Plus integrated HPLC
Shimadzu’s i-Series Plus expands the product line and improves performance and user-friendliness. With i-Series Plus, pretreatment operations have been automated, such as the processes to dilute samples and add reagents. This results in better reproducibility and measurement accuracy by minimizing human error, to ensure reliable data in the analysis of pharmaceuticals and foods. i-Series Plus also offers new features that satisfy data integrity requirements of the pharmaceutical industry. The i-Series Plus consists of the compact HPLC Prominence-i and UHPLC system Nexera-i.
For more information please visit www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
